ONO Pharma - Navigating PCNSL

We built a modern content site to educate U.S. healthcare professionals on relapsed or refractory primary central nervous system lymphoma, a rare and aggressive cancer with no FDA‑approved treatments. The site tackles the lack of clinical-trial options and consensus on standard of care by aggregating expert insights, treatment challenges, and future outlooks in one accessible hub